These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 29800007

  • 41. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R, Otsuka A, Kaku Y, Honda T, Kabashima K.
    Eur J Dermatol; 2018 Feb 01; 28(1):84-85. PubMed ID: 29400292
    [No Abstract] [Full Text] [Related]

  • 42. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R, Hussain A, DeAngelis D.
    Orbit; 2018 Oct 01; 37(5):381-384. PubMed ID: 29381409
    [Abstract] [Full Text] [Related]

  • 43. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE, Loochtan AI, Bedlack RS.
    Muscle Nerve; 2018 Apr 01; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.
    Totonchy MB, Ezaldein HH, Ko CJ, Choi JN.
    JAMA Dermatol; 2016 May 01; 152(5):590-2. PubMed ID: 26675815
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS.
    J Am Acad Dermatol; 2019 Apr 01; 80(4):990-997. PubMed ID: 30399387
    [Abstract] [Full Text] [Related]

  • 49. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.
    Galmiche S, Lheure C, Kramkimel N, Franck N, Boitier F, Dupin N, Turc G, Psimaras D, Aractingi S, Guégan S.
    J Eur Acad Dermatol Venereol; 2019 Dec 01; 33(12):e440-e443. PubMed ID: 31219194
    [No Abstract] [Full Text] [Related]

  • 50. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
    Numata S, Iwata Y, Okumura R, Arima M, Kobayashi T, Watanabe S, Suzuki K, Horiguchi M, Sugiura K.
    J Dermatol; 2018 Jan 01; 45(1):113-114. PubMed ID: 28225147
    [No Abstract] [Full Text] [Related]

  • 51. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
    Abdallah AO, Herlopian A, Ravilla R, Bansal M, Chandra-Reddy S, Mahmoud F, Ong S, Gokden M, Hutchins L.
    J Oncol Pharm Pract; 2016 Jun 01; 22(3):537-42. PubMed ID: 25712627
    [Abstract] [Full Text] [Related]

  • 52. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 01; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 53. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG.
    Exp Dermatol; 2016 Jul 01; 25(7):553-4. PubMed ID: 27061281
    [No Abstract] [Full Text] [Related]

  • 54. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N, Uchi H, Furue M.
    J Dermatol; 2017 Oct 01; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract] [Full Text] [Related]

  • 55. Remote-onset alopecia areata attributed to ipilimumab.
    Pearson DR, Lewis K, Alkousakis T.
    Cutis; 2019 Dec 01; 104(6):E25-E27. PubMed ID: 31939941
    [Abstract] [Full Text] [Related]

  • 56. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
    van den Brom RR, Abdulahad WH, Rutgers A, Kroesen BJ, Roozendaal C, de Groot DJ, Schröder CP, Hospers GA, Brouwer E.
    Rheumatology (Oxford); 2016 Jun 01; 55(6):1143-5. PubMed ID: 27069016
    [No Abstract] [Full Text] [Related]

  • 57. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A, Shah U, Khine H, Vandergriff T, Froehlich T.
    Melanoma Res; 2017 Apr 01; 27(2):171-173. PubMed ID: 28099367
    [No Abstract] [Full Text] [Related]

  • 58. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
    Hoadley A, Sandanayake N, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):434-435. PubMed ID: 27864215
    [No Abstract] [Full Text] [Related]

  • 59. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Başsorgun I, Coşkun HŞ.
    J Oncol Pharm Pract; 2016 Jun 01; 22(3):533-6. PubMed ID: 25694346
    [Abstract] [Full Text] [Related]

  • 60. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P.
    J Am Acad Dermatol; 2016 Mar 01; 74(3):455-61.e1. PubMed ID: 26793994
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.